BioCryst Pharmaceuticals (BCRX) said Monday that interim trial data showed that an oral granule formulation of Orladeyo (berotralstat) demonstrated sustained reductions in monthly attack rates in pediatric patients aged 2 to less than 12 with hereditary angioedema.
After taking Orladeyo for one month, median and mean monthly attack rates dropped to 0 and 0.5 attacks per month, compared with 0.96 and 1.5 with standard-of-care, the biotechnology firm said.
The median attack rate remained at 0 through month 12, the company said, adding that Orladeyo's oral granule formulation was found to be safe and tolerated.
"We remain on track to submit our new drug application to the FDA this year," said Helen Thackray, chief research and development officer of BioCryst.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。